Clinical Trials Browser

Phase 1 × OTHER × ALT-803 × Clear all

Lymphoma, B-Cell

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Genitourinary

Carcinoma, Transitional Cell

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

11 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02890758 2023-02-21

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Phase 1 Completed

14 enrolled

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Colonic Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

CARMEN-803

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

CIML NK Cell in Head & Neck Cancer

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803